When it comes to treating conditions like rheumatoid arthritis, patients often have to weigh the costs and benefits of different medications. Two popular options for managing this chronic condition are Rinvoq and Xeljanz. Both medications are considered Janus kinase (JAK) inhibitors and work by targeting specific enzymes in the body that play a role in the inflammatory response.
One of the key factors that patients consider when choosing between Rinvoq and Xeljanz is the cost. The price of these medications can vary depending on a variety of factors, including insurance coverage, pharmacy discounts, and whether the medication is available in generic form.
Rinvoq, which contains the active ingredient upadacitinib, is a newer medication that was approved by the FDA in 2019. It is typically taken once a day and comes in tablet form. The average retail price for a 30-day supply of Rinvoq ranges from $3,000 to $3,400, depending on the dosage strength.
Xeljanz, on the other hand, contains the active ingredient tofacitinib and has been on the market since 2012. It is also taken orally and is available in both immediate-release and extended-release formulations. The average retail price for a 30-day supply of Xeljanz ranges from $2,500 to $3,000, depending on the dosage strength and formulation.
Ultimately, the choice between Rinvoq and Xeljanz will depend on a variety of factors, including the patient's individual health needs, insurance coverage, and budget. Patients should work closely with their healthcare provider to determine the best treatment option for their specific situation.
In conclusion, Rinvoq and Xeljanz are both effective medications for managing rheumatoid arthritis, but they come with different price tags. Patients should carefully consider the cost of these medications, as well as other factors, when making a decision about their treatment plan.